Ignite Creation Date:
2024-05-06 @ 2:35 PM
Last Modification Date:
2024-10-26 @ 1:33 PM
Study NCT ID:
NCT04365101
Status:
UNKNOWN
Last Update Posted:
2022-05-25
First Post:
2020-04-22
Brief Title:
Natural Killer Cell CYNK-001 Infusions in Adults With COVID-19
Sponsor:
Celularity Incorporated
Organization:
Celularity Incorporated
Study Overview
Official Title:
A Phase III Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells CYNK-001 for the Treatment of Adults With COVID-19
Status:
UNKNOWN
Status Verified Date:
2022-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CYNKCOVID
Brief Summary:
This study is a Phase 1 2 trial to determine the safety and efficacy of CYNK-001 an immunotherapy containing Natural Killer NK cells derived from human placental CD34 cells and culture-expanded in patients with moderate COVID-19 disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None